Literature DB >> 20974246

An IL-1 receptor antagonist blocks a morphine-induced attenuation of locomotor recovery after spinal cord injury.

Michelle A Hook1, Stephanie N Washburn, Georgina Moreno, Sarah A Woller, Denise Puga, Kuan H Lee, James W Grau.   

Abstract

Morphine is one of the most commonly prescribed medications for the treatment of chronic pain after a spinal cord injury (SCI). Despite widespread use, however, little is known about the secondary consequences of morphine use after SCI. Unfortunately, our previous studies show that administration of a single dose of morphine, in the acute phase of a moderate spinal contusion injury, significantly attenuates locomotor function, reduces weight gain, and produces symptoms of paradoxical pain (Hook et al., 2009). The current study focused on the cellular mechanisms that mediate these effects. Based on data from other models, we hypothesized that pro-inflammatory cytokines might play a role in the morphine-induced attenuation of function. Experiment 1 confirmed that systemic morphine (20 mg/kg) administered one day after a contusion injury significantly increased expression levels of spinal IL-1β 24 h later. Experiment 2 extended these findings, demonstrating that a single dose of morphine (90 μg, i.t.) applied directly onto the spinal cord increased expression levels of spinal IL-1β at both 30 min and 24 h after administration. Experiment 3 showed that administration of an interleukin-1 receptor antagonist (IL-1ra, i.t.) prior to intrathecal morphine (90 μg), blocked the adverse effects of morphine on locomotor recovery. Further, pre-treatment with 3 μg IL-1ra prevented the increased expression of at-level neuropathic pain symptoms that was observed 28 days later in the group treated with morphine-alone. However, the IL-1ra also had adverse effects that were independent of morphine. Treatment with the IL-1ra alone undermined recovery of locomotor function, potentiated weight loss and significantly increased tissue loss at the injury site. Overall, these data suggest that morphine disrupts a critical balance in concentrations of pro-inflammatory cytokines in the spinal cord, and this undermines recovery of function. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974246      PMCID: PMC3025088          DOI: 10.1016/j.bbi.2010.10.018

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  56 in total

1.  Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment.

Authors:  S M Knoblach; L Fan; A I Faden
Journal:  J Neuroimmunol       Date:  1999-03-01       Impact factor: 3.478

2.  Microglia-neuronal signalling in neuropathic pain hypersensitivity 2.0.

Authors:  Simon Beggs; Michael W Salter
Journal:  Curr Opin Neurobiol       Date:  2010-08       Impact factor: 6.627

3.  Shock-induced hyperalgesia: II. Role of the dorsolateral periaqueductal gray.

Authors:  S McLemore; E D Crown; M W Meagher; J W Grau
Journal:  Behav Neurosci       Date:  1999-06       Impact factor: 1.912

4.  The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1beta on long-term potentiation in the rat dentate gyrus in vitro.

Authors:  A N Coogan; L A O'Neill; J J O'Connor
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 5.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

6.  Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation.

Authors:  C A Murray; M A Lynch
Journal:  J Neurosci       Date:  1998-04-15       Impact factor: 6.167

7.  P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation.

Authors:  Tuan Trang; Simon Beggs; Xiang Wan; Michael W Salter
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

8.  Intrathecal morphine attenuates recovery of function after a spinal cord injury.

Authors:  Michelle A Hook; Georgina Moreno; Sarah Woller; Denise Puga; Kevin Hoy; Robyn Balden; James W Grau
Journal:  J Neurotrauma       Date:  2009-05       Impact factor: 5.269

9.  Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia.

Authors:  Mark R Hutchinson; Benjamen D Coats; Susannah S Lewis; Yingning Zhang; David B Sprunger; Niloofar Rezvani; Eric M Baker; Brian M Jekich; Julie L Wieseler; Andrew A Somogyi; David Martin; Stephen Poole; Charles M Judd; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2008-07-02       Impact factor: 7.217

10.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

View more
  24 in total

1.  MicroRNA dysregulation following spinal cord contusion: implications for neural plasticity and repair.

Authors:  E R Strickland; M A Hook; S Balaraman; J R Huie; J W Grau; R C Miranda
Journal:  Neuroscience       Date:  2011-04-07       Impact factor: 3.590

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  Sex differences in μ-opioid receptor expression in trigeminal ganglia under a myositis condition in rats.

Authors:  X Zhang; Y Zhang; J Asgar; K Y Niu; J Lee; K S Lee; M Schneider; J Y Ro
Journal:  Eur J Pain       Date:  2013-06-25       Impact factor: 3.931

4.  Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Authors:  Miriam Aceves; Eric A Bancroft; Alejandro R Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-11-04       Impact factor: 5.269

5.  Analgesia or addiction?: implications for morphine use after spinal cord injury.

Authors:  Sarah A Woller; Georgina L Moreno; Nigel Hart; Paul J Wellman; James W Grau; Michelle A Hook
Journal:  J Neurotrauma       Date:  2012-04-02       Impact factor: 5.269

6.  The association between spinal cord trauma-sensitive miRNAs and pain sensitivity, and their regulation by morphine.

Authors:  Eric R Strickland; Sarah A Woller; Michelle A Hook; James W Grau; Rajesh C Miranda
Journal:  Neurochem Int       Date:  2014-05-24       Impact factor: 3.921

7.  Neurobiological Effects of Morphine after Spinal Cord Injury.

Authors:  Michelle A Hook; Sarah A Woller; Eric Bancroft; Miriam Aceves; Mary Katherine Funk; John Hartman; Sandra M Garraway
Journal:  J Neurotrauma       Date:  2016-11-02       Impact factor: 5.269

Review 8.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

9.  Morphine self-administration following spinal cord injury.

Authors:  Sarah A Woller; Jamal S Malik; Miriam Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2014-07-24       Impact factor: 5.269

10.  A novel bifunctional protein TNFR2-Fc-IL-1ra (TFI): expression, purification and its neutralization activity of inflammatory factors.

Authors:  Bo Xie; Shan Liu; Shuyin Wu; Alan Chang; Weiyuan Jin; Zhixiang Guo; Shuaidong Ye; Mizhou Hui
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.